During Jazz Pharmaceuticals’ earnings call, CEO Bruce Cozadd highlighted the company’s interest in expanding through strategic deals. Jazz is looking to diversify by exploring opportunities in neuroscience, cancer treatments, and rare diseases. They are focusing on stable revenue, efficient sales, and aligning with their research capabilities.
Cozadd also mentioned a positive development for their key product, Epidiolex, used to treat seizures. Jazz settled with companies trying to create generic versions, delaying competition until the late 2030s. This ensures strong revenue for Jazz and encourages more mergers and acquisitions (M&A).
Epidiolex, acquired through a $7.2 billion deal with GW Pharmaceuticals, is expected to become a blockbuster, with sales reaching $972 million in 2024. Despite no major M&A moves since then, Jazz’s CFO, Philip Johnson, assured that the company is actively seeking opportunities. Jazz expects 2025 revenues between $4.15 billion and $4.4 billion.
Jazz also discussed Ziihera, a drug for HER2-positive biliary tract cancer, which could achieve over $2 billion in peak sales. The company delayed a phase 3 trial for Ziihera in gastroesophageal cancer to late 2025 due to slower-than-expected tumor progression.
Finally, Cozadd announced his plans to step down as CEO by the end of 2025, though he will stay on as chairman. The search for his successor is underway, but Cozadd emphasized taking the time to find the right person.